Why This Biotech Stock Just Rocketed 64% After Hitting A 4-Year High

Shares of Acadia Pharmaceuticals rocketed Monday after the biotech company said its psychosis treatment met its key goal in a Phase 3 test. The drug already sells under the name Nuplazid.

The post Why This Biotech Stock Just Rocketed 64% After Hitting A 4-Year High appeared first on Investor’s Business Daily.

Author: ALLISON GATLIN | Source

This article does not constitute investment advice. We are not affiliated or responsible for content hosted on 3rd-party sites in any way.

Click here for great deals & savings!